Advertisement

Topics

Abzena Plc starting to see the benefits of its capital investment programme

11:05 EDT 16 Apr 2018 | Proactive Investors

John Burt, chief executive of Abzena plc (AIM:ABZA), tells Proactive's Andrew Scott the group expects turnover for the 12 months to the end of March to be in the order of £22mln, up 18% on the year before, with underlying earnings (EBITDA) in line with expectations.

There was a marked split between halves, with sales up 49% in the second six months compared with the first.

Abzena's targeting top-line growth in 2019 at a “slightly higher rate” than 2018, with the performance expected to be second-half weighted.

Original Article: Abzena Plc starting to see the benefits of its capital investment programme

NEXT ARTICLE

More From BioPortfolio on "Abzena Plc starting to see the benefits of its capital investment programme"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...